Who Makes Ozempic and Wegovy? Understanding the Creator Behind These Popular Medications

Last reviewed: July 9, 2026

Last updated: July 9, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Novo Nordisk, a Danish pharmaceutical company, developed semaglutide and brought it to market under two brand names: Ozempic for type 2 diabetes management and Wegovy for chronic weight management. Both medications contain the same active compound—a glucagon-like peptide-1 (GLP-1) receptor agonist that signals fullness to the brain and slows stomach emptying. PlexusDx now offers compounded semaglutide injections from licensed 503A pharmacies, giving patients access to this proven mechanism at significantly lower costs without requiring insurance.

Novo Nordisk's Development of Semaglutide: The Timeline

Novo Nordisk began semaglutide research in the late 1990s as part of a broader effort to create longer-acting GLP-1 therapies. The company successfully synthesized the compound by modifying the natural human GLP-1 hormone, adding a fatty acid chain that allows the medication to bind to proteins in the bloodstream. This modification extends semaglutide's half-life to approximately seven days, enabling once-weekly dosing rather than the daily injections required by earlier GLP-1 drugs.

The FDA approved semaglutide for type 2 diabetes in December 2017 under the brand name Ozempic. Clinical trials showed it reduced HbA1c levels by 1.5 to 1.8 percentage points in patients with suboptimal glycemic control. Two years later, in November 2019, the FDA granted approval for Wegovy, the higher-dose weight loss formulation, following the STEP clinical trial program that demonstrated an average weight reduction of 15% over 68 weeks.

How Semaglutide Works: Understanding the Medication Mechanism

Semaglutide mimics the body's natural GLP-1 hormone, which regulates appetite and blood sugar. When semaglutide binds to GLP-1 receptors in the hypothalamus—the brain region controlling hunger—it triggers signals that reduce food cravings and increase feelings of satiety. The medication also slows gastric emptying, meaning food stays in the stomach longer, further extending the sensation of fullness between meals.

This multi-pathway mechanism explains why semaglutide produces weight loss independent of calorie restriction alone. In the STEP 3 trial, participants achieved a 17.4% reduction in body weight after 68 weeks, with improvements in cardiometabolic risk factors including blood pressure, triglycerides, and C-reactive protein. The medication's effectiveness depends partly on individual genetic variations in GLP-1 receptor sensitivity and other metabolic pathways that PlexusDx can assess through the Precision Peptide Genetic Test.

Branded Ozempic and Wegovy Versus Compounded Semaglutide

Both branded Novo Nordisk products and compounded semaglutide contain identical active ingredients manufactured under strict pharmaceutical standards. Compounded versions are prepared by licensed 503A pharmacies, which operate under FDA oversight and must follow United States Pharmacopeia (USP) quality guidelines. The key difference lies in pricing and accessibility: branded medications often cost $1,000 to $1,500 per month even with insurance, while PlexusDx compounded semaglutide injections start at $189/mo (or $149/mo on the 6-month plan) without requiring insurance coverage.

PlexusDx sources semaglutide exclusively from licensed 503A compounding pharmacies, never from 503B (outsourcing) facilities. This commitment ensures patients receive individually prepared medications tailored to their needs. The compounded formulation undergoes the same sterility, potency, and purity testing as branded versions. HSA and FSA funds are eligible for PlexusDx compounded semaglutide, providing additional cost savings for eligible patients.

Personalized Semaglutide Therapy and Genetic Insights at PlexusDx

Individual responses to semaglutide vary significantly based on genetic factors affecting GLP-1 receptor expression and related metabolic pathways. The Precision Peptide Genetic Test from PlexusDx analyzes key variants including GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313. These genetic markers influence how efficiently your body responds to GLP-1 therapy, helping PlexusDx providers optimize dosing and medication selection for maximum results.

PlexusDx maps 14 distinct metabolic pathways, 49 peptides, and 150+ genetic insights related to weight management and appetite regulation. By combining genetic data with clinical assessment, PlexusDx helps identify whether compounded semaglutide injection is your optimal choice or whether alternatives like tirzepatide or combination protocols might yield better outcomes. The Precision Peptide Genetic Test costs $99 as an add-on after your first month of treatment and provides insights that apply throughout your entire weight loss journey.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $189/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is compounded semaglutide from PlexusDx the same as Wegovy?

Yes—both contain identical semaglutide active ingredient. The difference is that PlexusDx sources from licensed 503A pharmacies and costs significantly less ($189/mo vs. $1,000+/mo for branded Wegovy) without requiring insurance. Your dose may need to go up. Your price won't.

What clinical evidence supports semaglutide for weight loss?

The STEP trials demonstrated that semaglutide produces average weight reductions of 15% to 17.4% over 68 weeks, with sustained improvements in cardiovascular risk factors. These results are supported by data from over 4,500 participants across multiple trials published in peer-reviewed journals.

Why does PlexusDx only use 503A compounding pharmacies?

503A pharmacies prepare individual prescriptions under direct FDA oversight and USP standards, ensuring sterility and purity equivalent to branded medications. This is different from 503B outsourcing facilities, which operate under different regulatory frameworks. PlexusDx prioritizes patient safety through this stricter standard.

Can I use my HSA or FSA to pay for PlexusDx semaglutide?

Yes. PlexusDx compounded semaglutide is HSA and FSA eligible, providing tax-advantaged savings on top of the already affordable $189/month starting price. No insurance is required, and no membership fees apply.

How does the Precision Peptide Genetic Test improve my semaglutide results?

The test identifies your genetic variants in GLP-1 receptor sensitivity, appetite regulation, and fat metabolism. These insights help PlexusDx providers determine if semaglutide is your best option or if tirzepatide or combination therapy would produce better outcomes based on your specific genetic profile.

Related Reading

• Wegovy Vs Ozempic 2
• Ozempic Vs Wegovy 2
• Ozempic And Wegovy
• Ozempic Vs Wegovy

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.